RxDoctor Payments DataLook up a doctor →

Alcibiades Rodriguez, MD

Clinical Neurophysiology · New York, NYNPI 1831151281

Payments from drug & device makers

$715,631in general payments, 2019–2025

Across 896 payments — averaging $798.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$321K
  • Axsome Therapeutics, Inc.$144K
  • Lilly USA, LLC$100K
  • Harmony Biosciences LLC$82K
  • Avadel CNS Pharmaceuticals, LLC$59K
  • Eisai Inc.$5K
  • plus $5K from 14 others

What the payments were for

  • Consulting fees$123,30417%
  • Speaking & faculty fees$471,33566%
  • Travel & lodging$92,44513%
  • Food & beverage$26,3684%
  • Education$6790%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$715,631 in reported general payments places this provider in the 95th percentile of 35 clinical neurophysiology providers in New York.

See all clinical neurophysiology providers in New York

Medicare billing

Part B allowed, 2024
$172,429
Medicare patients
413
Services billed
664

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XywavSodium,calcium,mag,pot Oxybate31$619,141
WakixPitolisant Hcl20$311,499
LumryzSodium Oxybate12$239,796
VimpatLacosamide13$65,927
BriviactBrivaracetam13$39,500
SunosiSolriamfetol Hcl30$31,567
LunestaEszopiclone24$20,665
Adderall XrDextroamphetamine/Amphetamine14$7,357
Zaleplon102$2,205
Doxepin Hcl38$1,284
Quetiapine Fumarate27$812
Zolpidem Tartrate94$583
Gabapentin42$501
Eszopiclone37$428
Trazodone Hcl27$289

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Harmony Biosciences LLCWakix$82,146$311,49920 claims
Avadel CNS Pharmaceuticals, LLCLumryz$59,086$239,79612 claims
UCB, Inc.Vimpat, Briviact$355$105,42826 claims
Axsome Therapeutics, Inc.Sunosi$143,845$31,56730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 35 clinical neurophysiology providers in New York.

Other clinical neurophysiology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →